Diffuse dermal mucinosis secondary to colony-stimulating factor 1 receptor monoclonal antibody treatment: A novel and peculiar drug-induced diffuse cutaneous mucinosis

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Olmos Alpiste, Ferran
• dc.contributor.author Segura Tigell, Sonia
• dc.contributor.author Tomás-Velázquez, Alejandra
• dc.contributor.author Aguado, Leyre
• dc.contributor.author España, Agustín
• dc.contributor.author Arriola Aperribay, Edurne
• dc.contributor.author Martín-Algarra, Salvador
• dc.contributor.author Barranco Sanz, Luis Carlos
• dc.contributor.author Lloreta, Josep, 1958-
• dc.contributor.author Pujol Vallverdú, Ramon Maria
• dc.date.accessioned 2021-10-22T07:31:17Z
• dc.date.issued 2021
• dc.description.abstract Colony-stimulating factor 1 receptor (CSF1R) inhibitors represent a new class of immune-modulatory drugs, mostly investigated in clinical trials in different malignant neoplasms. Four patients, diagnosed with recurrent or advanced malignant neoplasm and treated with a combination of anti-programmed death ligand 1 and anti-CSF1R monoclonal antibodies, developed an asymptomatic cutaneous eruption characterized by an ill-defined pseudoedematous to waxy diffuse infiltration with a reticular cobblestone-like pattern. Histopathological examination revealed diffuse mucin deposition involving the superficial and mid-dermis with fragmented and scattered elastic fibers. The exact pathogenic mechanisms implicated in the development of mucin deposits in patients treated with CSF1R inhibitors remain to be elucidated. A reduced degradation and clearance of components of the extracellular matrix by macrophages secondary to CSF1 pathway inhibition may be hypothesized. Shredding and fragmentation of elastic fibers may be a result of the increased accumulation of mucopolysaccharides. This observation illustrates the new spectrum of skin-related toxicities secondary to new targeting therapies. This may contribute to a better understanding of the underlying pathogenic mechanisms in skin diseases characterized by a persistent dermal glycosaminoglycan deposition.
• dc.format.mimetype application/pdf
• dc.identifier.citation Olmos-Alpiste F, Segura S, Tomás-Velázquez A, Aguado L, España A, Arriola E, Martín-Algarra S, Barranco C, Lloreta J, Pujol RM. Diffuse dermal mucinosis secondary to colony-stimulating factor 1 receptor monoclonal antibody treatment: A novel and peculiar drug-induced diffuse cutaneous mucinosis. J Dermatol. 2021; 48(3):380-4. DOI: 10.1111/1346-8138.15662
• dc.identifier.doi http://dx.doi.org/10.1111/1346-8138.15662
• dc.identifier.issn 0385-2407
• dc.identifier.uri http://hdl.handle.net/10230/48759
• dc.language.iso eng
• dc.publisher Wiley
• dc.rights This is the peer reviewed version of the following article: Olmos-Alpiste F, Segura S, Tomás-Velázquez A, Aguado L, España A, Arriola E, Martín-Algarra S, Barranco C, Lloreta J, Pujol RM. Diffuse dermal mucinosis secondary to colony-stimulating factor 1 receptor monoclonal antibody treatment: A novel and peculiar drug-induced diffuse cutaneous mucinosis. J Dermatol. 2021; 48(3):380-4. DOI: 10.1111/1346-8138.15662, which has been published in final form at http://dx.doi.org/10.1111/1346-8138.15662. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.keyword Anti-programmed death ligand 1
• dc.subject.keyword Colony-stimulating factor 1 receptor inhibitor
• dc.subject.keyword Dermal mucinosis
• dc.subject.keyword Drug reaction
• dc.subject.keyword Skin toxicity
• dc.title Diffuse dermal mucinosis secondary to colony-stimulating factor 1 receptor monoclonal antibody treatment: A novel and peculiar drug-induced diffuse cutaneous mucinosis
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion